Pirfenidone, a novel antifibrotic and anti-inflammatory drug, inhibits the synthesis of TGF-beta, a chemical mediator that controls many cell functions including proliferation and differentiation, and plays a key
Decrease in reagent sales led to the decrease in revenue, the company said. Gross profit decreased 51.2% to $2,115,000 from $2,488,000 due to lower sales and the decrease
The company has reported a net loss of $4.37m, or $2.09 loss per diluted share, compared to net loss of $7.34m or $3.90 loss per diluted share, for
Gliclazide is an oral sulfonylurea hypoglycemic agent which stimulates insulin secretion which stimulates beta cells of the islet of Langerhans in the pancreas to release insulin. Gliclazide is
The project starts out with an initial investment of £5m from each partner over a three year period. The collaboration between two UK based pharmaceutical companies, GSK and
The company’s loss from operations was $7.39m, compared to $5.76m for the same period last year. Total operating expenses for the first quarter ended 31 March 2011 were
The Phase I study will investigate the safety, immunological and the biological effect of the drug in patients who are suffering from melanoma. Through intratumoral injection, Ad-RTS-IL-12 employs
SFP is an investigational, continuous iron therapy in late-stage clinical development designed to treat end-stage renal disease (ESRD) patients. Clinical trial data suggests that SFP, delivered via dialysate
As per the terms of the agreement, all the companies will jointly organize research and development to evaluate the feasibility of developing various ophthalmic solutions applying Activus Pure
Brightwell Technologies is a provider in Micro-Flow Imaging (MFI), an analytical technique used to detect particles and aggregates in protein-based therapeutics. Cell Biosciences has raised $13m in a
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.